A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

NCT05817435 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence

Interventions

BIOLOGICAL: efgartigimod PH20 SC as a prefilled syringe presentation
BIOLOGICAL: efgartigimod PH20 SC as a vial + syringe presentation

Sponsor

argenx